Stockscreener 앱 받기
300.09
0.39%
0.64
전일 마감가:
$299.45
열려 있는:
$302.03
하루 거래량:
76,202
Relative Volume:
0.27
시가총액:
$8.84B
수익:
$389.13M
순이익/손실:
$204.83M
주가수익비율:
43.85
EPS:
6.8443
순현금흐름:
$188.91M
1주 성능:
+2.50%
1개월 성능:
+10.31%
6개월 성능:
+37.46%
1년 성능:
+140.40%
1일 변동 폭
$298.99
$303.87
1주일 범위
$296.13
$309.41
52주 변동 폭
$123.03
$319.48
Krystal Biotech Inc Stock (KRYS) Company Profile
명칭
Krystal Biotech Inc
전화
(412) 586-5830
주소
2100 WHARTON STREET, PITTSBURGH, PA
Compare KRYS vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
KRYS
Krystal Biotech Inc
|
299.93 | 8.83B | 389.13M | 204.83M | 188.91M | 6.8443 |
VRTX
Vertex Pharmaceuticals Inc
|
437.04 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
636.90 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
804.14 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
297.00 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
153.80 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Krystal Biotech Inc Stock (KRYS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-27 | 개시 | Wolfe Research | Peer Perform |
| 2026-01-06 | 업그레이드 | Citigroup | Neutral → Buy |
| 2025-03-05 | 개시 | Jefferies | Buy |
| 2024-08-06 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2023-11-20 | 개시 | Goldman | Buy |
| 2023-10-24 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-10-12 | 개시 | Citigroup | Buy |
| 2023-09-07 | 개시 | Berenberg | Buy |
| 2023-04-18 | 개시 | Stifel | Buy |
| 2023-02-28 | 업그레이드 | Goldman | Neutral → Buy |
| 2022-08-25 | 다운그레이드 | Goldman | Buy → Neutral |
| 2022-01-18 | 개시 | BofA Securities | Buy |
| 2021-07-20 | 업그레이드 | Goldman | Neutral → Buy |
| 2020-09-18 | 개시 | B. Riley FBR | Buy |
| 2020-06-04 | 개시 | Evercore ISI | Outperform |
| 2019-09-24 | 개시 | Goldman | Neutral |
| 2019-08-06 | 재확인 | H.C. Wainwright | Buy |
| 2019-06-24 | 재확인 | Chardan Capital Markets | Buy |
| 2019-06-24 | 재확인 | H.C. Wainwright | Buy |
| 2019-05-30 | 개시 | Guggenheim | Buy |
| 2018-09-11 | 개시 | Cantor Fitzgerald | Overweight |
모두보기
Krystal Biotech Inc 주식(KRYS)의 최신 뉴스
Krystal Biotech (KRYS) Investor Outlook: Robust Growth Prospects with 8.32% Potential Upside - DirectorsTalk Interviews
Precision Trading with Krystal Biotech Inc. (KRYS) Risk Zones - Stock Traders Daily
Krystal Biotech Inc at Bank of America Global Healthcare Conference Transcript - GuruFocus
BofA Securities Maintains Krystal Biotech(KRYS.US) With Buy Rating, Announces Target Price $364 - Moomoo
KRYS Reiterates by HC Wainwright & Co. -- Price Target Maintained at $310 - GuruFocus
KRYS Technical Analysis | Trend, Signals & Chart Patterns | KRYSTAL BIOTECH INC (NASDAQ:KRYS) - ChartMill
Krystal Biotech outlines $175M-$195M 2026 non-GAAP opex while targeting 6 data readouts before year-end - MSN
Krystal Biotech, Inc. Files Form 8-K with SEC Detailing Company Information and Annual Meeting Results - Minichart
Krystal Biotech Shareholders Approve Directors and Compensation - TipRanks
The Bull Case For Krystal Biotech (KRYS) Could Change Following UK Vyjuvek Approval And Rising Profitability - Sahm
Krystal Biotech Inc stock (US5012681064): HC Wainwright confirms Buy as UK clears VYJUVEK - AD HOC NEWS
Krystal Biotech gains regulatory approval to sell gene therapy in the United Kingdom - The Business Journals
Krystal Biotech Q1 earnings & sales beat estimates, pipeline in focus - MSN
Krystal Biotech receives UK approval for gene therapy VYJUVEK By Investing.com - Investing.com South Africa
Krystal Biotech receives UK approval for gene therapy VYJUVEK - Investing.com
Krystal Biotech's (KRYS) Buy Rating Reaffirmed at HC Wainwright - MarketBeat
Krystal Biotech Announces United Kingdom MHRA Approval of VYJUVEK® for the Treatment of Dystrophic Epidermolysis Bullosa - The Manila Times
First UK genetic medicine for DEB lets some patients treat wounds at home - Stock Titan
Krystal Biotech Price Target Maintained With a $310.00/Share by HC Wainwright & Co. - Moomoo
Krystal Biotech, Inc. (KRYS) Stock Analysis: Strong Buy Ratings and Promising 5.38% Upside Potential - DirectorsTalk Interviews
Krystal Biotech Inc stock (US5012681064): gene therapy player draws attention after shareholder meet - AD HOC NEWS
VIRGINIA RETIREMENT SYSTEMS ET Al Grows Stock Holdings in Krystal Biotech, Inc. $KRYS - MarketBeat
Assessing Krystal Biotech (KRYS) Valuation After First Quarter Earnings and EPS Growth - Sahm
Krystal Biotech, Inc. (NASDAQ:KRYS) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
Krystal Biotech (KRYS) Receives Approval for Innovative Wound Tr - GuruFocus
KRYS: All proposals, including director elections and compensation policies, were approved - TradingView
Krystal Biotech's Medicine to Treat Wounds in Dystrophic Epidermolysis Bullosa Gets Approval in UK - Moomoo
Krystal Biotech Inc Annual Shareholders Meeting Transcript - GuruFocus
Krystal Biotech Inc Phase 1/2 Clinical Trial of KB103 Final Update Call Transcript - GuruFocus
Krystal Biotech Inc at TD Cowen Healthcare Conference Transcript - GuruFocus
BofA Securities Maintains Krystal Biotech(KRYS.US) With Buy Rating - Moomoo
Why is Krystal Biotech (KRYS) down 11.5% since last earnings report? - MSN
Krystal Biotech, Inc. Stock 12‑Month Price Target Raised to $330.56, Implies 6% Upside - TradingView
Krystal Biotech stock (US5012681064): Hits all-time high near $316 - AD HOC NEWS
Technical Reactions to KRYS Trends in Macro Strategies - Stock Traders Daily
Krystal Biotech stock hits all-time high at 315.68 USD By Investing.com - Investing.com India
There May Be Underlying Issues With The Quality Of Krystal Biotech's (NASDAQ:KRYS) Earnings - simplywall.st
Krystal Biotech stock hits all-time high at 315.68 USD - Investing.com
This Profitable Biotech Stealthily Climbs Into A Buy Zone - Investor's Business Daily
Krystal Biotech (NASDAQ:KRYS) Hits New 52-Week HighHere's Why - MarketBeat
Krystal Biotech's (NASDAQ:KRYS) Earnings Are Of Questionable Quality - Moomoo
Krystal Biotech (KRYS) Is Up 6.5% After Vyjuvek-Fueled Q1 Profit Jump And Investor Conference Update - Yahoo Finance
Krystal Biotech, Inc. (KRYS) Stock Analysis: Strong Buy Ratings Signal Promising Upside - DirectorsTalk Interviews
State of New Jersey Common Pension Fund D Reduces Stock Position in Krystal Biotech, Inc. $KRYS - MarketBeat
symbol__ Stock Quote Price and Forecast - CNN
Krystal Biotech (KRYS) Is Up 13.1% After Strong Q1 Earnings And FDA Nod For At-Home Vyjuvek Use – Has The Bull Case Changed? - Sahm
Krystal Biotech: Vyjuvek Is Not The Primary Asset (NASDAQ:KRYS) - Seeking Alpha
Krystal Biotech, Inc. $KRYS Shares Purchased by Principal Financial Group Inc. - MarketBeat
A Look At Krystal Biotech (KRYS) Valuation After Vyjuvek Powered Q1 2026 Earnings Beat - simplywall.st
KRYS Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Krystal Biotech (NASDAQ:KRYS) Combines Perfect Trend Template with High-Growth Momentum - ChartMill
Krystal Biotech Inc (KRYS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.25%
0.46%
자본화:
|
볼륨(24시간):